The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis.
#BladderCancer
#blcsm
TURBT
TURP
benign prostatic hyperplasia
bladder cancer
endoscopic surgery
simultaneous surgery
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
28
03
2020
revised:
23
05
2020
accepted:
29
05
2020
pubmed:
22
6
2020
medline:
27
4
2021
entrez:
22
6
2020
Statut:
ppublish
Résumé
To evaluate recurrence and progression risk after simultaneous endoscopic surgery of bladder cancer and benign prostatic hyperplasia (BPH), as simultaneous surgery is not an unusual scenario and theoretically simultaneous transurethral resection of bladder tumour (TURBT) and transurethral resection of the prostate (TURP) can lead to an increased risk of recurrence in the bladder neck and prostatic urethra (BN/PU). We conducted a systematic review and meta-analysis to assess the risk of recurrence (i.e. whole bladder and/or BN/PU) and tumour progression as outcomes after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone. We queried PubMed and Web of Science database on 1 January 2020. We used random- and/or fixed-effects meta-analytic models in the presence or absence of heterogeneity according to the I Nine retrospective and three clinical trial studies were selected after considering inclusion and exclusion criteria. We conducted the meta-analysis on retrospective and randomised controlled trials (RCTs) separately. Eight retrospective and three RCT studies were included to assess the BN/PU recurrence risk and the summarised risk ratio (RR) was 1.02 (95% confidence interval [CI] 0.74-1.41) and 0.93 (95% CI 0.47-1.84), respectively. Five retrospective and two RCT studies were included to assess the progression risk and the summarised RR was 0.91 (95% CI 0.56-1.48) and 1.16 (95% CI 0.30-4.51), respectively. Eight retrospective and three RCT studies were included to assess the whole bladder recurrence risk and the summarised RR was 0.87 (95% CI 0.78-0.97) and 0.89 (95% CI 0.65-1.21), respectively. We did not observe any increased risk of total bladder recurrence, BN/PU recurrence, or progression after a simultaneous endoscopic surgery of bladder tumour and BPH, as compared to TURBT alone.
Identifiants
pubmed: 32564458
doi: 10.1111/bju.15146
pmc: PMC7891376
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
143-152Informations de copyright
© 2020 The Authors BJU International published by John Wiley & Sons Ltd on behalf of BJU International.
Références
J Urol. 2009 Apr;181(4):1594-9; discussion 1599
pubmed: 19230913
Eur Urol. 1988;15(1-2):40-2
pubmed: 2463920
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Int Urol Nephrol. 2012 Oct;44(5):1325-33
pubmed: 22710969
Urology. 2007 Jul;70(1):55-9
pubmed: 17656208
Ann R Coll Surg Engl. 2010 Sep;92(6):519-24
pubmed: 20522307
World J Urol. 2021 Jan;39(1):105-111
pubmed: 32215675
Int Urol Nephrol. 2014 Apr;46(4):691-4
pubmed: 24097277
Eur Urol. 2012 Jul;62(1):118-25
pubmed: 22101115
Urology. 2010 Jun;75(6):1392-5
pubmed: 19781747
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
J Endourol. 2009 Dec;23(12):2007-11
pubmed: 19839745
J Urol. 1972 Mar;107(3):445-7
pubmed: 4110843
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Eur Urol. 2005 Nov;48(5):760-3
pubmed: 16005563
World J Urol. 2018 Oct;36(10):1629-1634
pubmed: 29725805
Nat Rev Dis Primers. 2017 Apr 13;3:17022
pubmed: 28406148
J Urol. 2003 Dec;170(6 Pt 1):2241-3
pubmed: 14634388
Aging Male. 2020 Feb 5;:1-12
pubmed: 32020826
J Urol. 1981 Aug;126(2):171-5
pubmed: 7265358